Evidence map›Paper›PMID 37502977›Full record

ArticlebioRxiv : the preprint server for biology2023

Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV.

Vitaliy A Matveev, Erik Z Mihelic, Erika Benko, Patrick Budylowski, Sebastian Grocott, Terry Lee, Chapin S Korosec, Karen Colwill, Henry Stephenson, Ryan Law and 26 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 9 institutions in 2 countries.

Vitaliy A MatveevDept of Medicine, University of Toronto, Toronto, ON, Canada.
Erik Z MihelicDept of Medicine, University of Toronto, Toronto, ON, Canada.
Erika BenkoMaple Leaf Medical Clinic, Toronto, ON, Canada.
Patrick BudylowskiDept of Medicine, University of Toronto, Toronto, ON, Canada.
Sebastian GrocottDept of Medicine, University of Toronto, Toronto, ON, Canada.
Terry LeeCIHR Canadian HIV Trials Network (CTN), Vancouver, BC, Canada.
Chapin S KorosecModelling Infection and Immunity Lab, Mathematics and Statistics Dept, York University, Toronto, ON, Canada.
Karen ColwillLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
Henry StephensonDept of Medicine, University of Toronto, Toronto, ON, Canada.
Ryan LawDept of Immunology, University of Toronto, Toronto, ON, Canada.
Lesley A WardDept of Immunology, University of Toronto, Toronto, ON, Canada.
Salma Sheikh-MohamedDept of Immunology, University of Toronto, Toronto, ON, Canada.
Geneviève MailhotLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
Melanie Delgado-BrandLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
Adrian PasculescuLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
Jenny H WangLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
Freda QiLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
Tulunay TursunLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
Lela KardavaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Serena ChauDept of Medicine, University of Toronto, Toronto, ON, Canada.
Philip SamaanDept of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Annam ImranDept of Medicine, University of Toronto, Toronto, ON, Canada.
Dennis C CopertinoInfectious Diseases, Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
Gary ChaoDept of Immunology, University of Toronto, Toronto, ON, Canada.
Yoojin ChoiDept of Immunology, University of Toronto, Toronto, ON, Canada.
Robert J ReinhardIndependent Public/Global Health Consultant, San Francisco, CA, USA.
Rupert KaulDept of Immunology, University of Toronto, Toronto, ON, Canada.
Jane M HeffernanModelling Infection and Immunity Lab, Mathematics and Statistics Dept, York University, Toronto, ON, Canada.
R Brad JonesInfectious Diseases, Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
Tae-Wook ChunLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Susan MoirLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Joel SingerCIHR Canadian HIV Trials Network (CTN), Vancouver, BC, Canada.
Jennifer GommermanDept of Immunology, University of Toronto, Toronto, ON, Canada.
Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada.
Colin KovacsMaple Leaf Medical Clinic, Toronto, ON, Canada.
Mario OstrowskiDept of Medicine, University of Toronto, Toronto, ON, Canada.
University of Toronto · CALunenfeld-Tanenbaum Research Institute · CANational Institutes of Health · USCornell University · USYork University · CACentre for Advancing Health Outcomes · CAMaple Leaf Medical Clinic · CASt. Michael's Hospital · CAUniversity of British Columbia · CA

Funding

REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
NIAID NIH HHS UM1 AI164565
6 · The paper itself

Abstract

Older individuals and people with HIV (PWH) were prioritized for COVID-19 vaccination, yet comprehensive studies of the immunogenicity of these vaccines and their effects on HIV reservoirs are not available. We followed 68 PWH aged 55 and older and 23 age-matched HIV-negative individuals for 48 weeks from the first vaccine dose, after the total of three doses. All PWH were on antiretroviral therapy (cART) and had different immune status, including immune responders (IR), immune non-responders (INR), and PWH with low-level viremia (LLV). We measured total and neutralizing Ab responses to SARS-CoV-2 spike and RBD in sera, total anti-spike Abs in saliva, frequency of anti-RBD/NTD B cells, changes in frequency of anti-spike, HIV gag/nef-specific T cells, and HIV reservoirs in peripheral CD4

Identifiers

PMID37502977
PMCPMC10370192
OpenAlexW4380738340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.